{"id":67123,"date":"2016-02-16T10:02:00","date_gmt":"2016-02-16T06:02:00","guid":{"rendered":"http:\/\/localhost\/?p=67123"},"modified":"2016-02-16T10:02:00","modified_gmt":"2016-02-16T06:02:00","slug":"biotech-company-scarx","status":"publish","type":"magazine","link":"https:\/\/brainstation.io\/magazine\/biotech-company-scarx","title":{"rendered":"Biotech Company ScarX Raises $2 Million to Commercialize New Scarring Treatment"},"content":{"rendered":"<p><img decoding=\"async\" style=\"margin: 11px 22px; float: right;\" src=\"https:\/\/c2.staticflickr.com\/2\/1630\/25043671076_ff3ccc42ee.jpg\" alt=\"\" width=\"349\" height=\"145\" \/>A Canadian biotechnology company commercializing innovative treatments for dermal scarring has raised venture capital.<\/p>\n<p><!-- pagebreak --><\/p>\n<p>Toronto&#8217;s ScarX Therapeutics has raised a Series A round worth $2 million to complete a clinical trial of its lead candidate in human volunteers.<\/p>\n<p>The company&rsquo;s investors in this financing round include Accel-Rx Health Sciences Accelerator, BDC Capital, and MaRS Innovation.<\/p>\n<p>ScarX Therapeutics is built upon Dr. Benjamin Alman&rsquo;s 30-year research career, and is based upon the novel finding that nefopam, a well-characterized small molecule which modulates a protein called beta-catenin that is associated with hypertrophic or excessive scarring in humans.<\/p>\n<p>&ldquo;In addition to the obvious cosmetic concerns, hyperplastic scars cause considerable disability, especially when they occur near a joint,&rdquo; said Dr. Alman, scientific founder and ScarX&rsquo;s chief science officer. &ldquo;While many factors play a role in excessive scarring, our work in the lab found that beta-catenin activation is a common mechanism for hypertrophic scars. Targeting beta-catenin with SCX-001 will prevent excessive scar formation in the vast majority of individuals, resulting in better cosmetic and functional outcomes from injury or surgery.&rdquo;<\/p>\n<p>&ldquo;ScarX is committed to bringing the first clinically meaningful prescription therapeutic to market,&rdquo; says Stephen Whitehead, president and CEO.<\/p>\n<p>Prior to today&rsquo;s financing, ScarX Therapeutics raised $1.7 million in dilutive and $1 million in non-dilutive funding to develop its lead candidate and complete pre-clinical studies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Canadian biotechnology company commercializing innovative treatments for dermal scarring has raised venture capital. Toronto&#8217;s ScarX Therapeutics has raised a Series A round worth $2 million to complete a clinical trial of its lead candidate in human volunteers. The company&rsquo;s investors in this financing round include Accel-Rx Health Sciences Accelerator, BDC Capital, and MaRS Innovation. [&hellip;]<\/p>\n","protected":false},"author":54503,"featured_media":67125,"menu_order":0,"template":"","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"magazine-region":[],"magazine-series":[],"magazine-topic":[],"class_list":["post-67123","magazine","type-magazine","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine\/67123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine"}],"about":[{"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/types\/magazine"}],"author":[{"embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/users\/54503"}],"version-history":[{"count":0,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine\/67123\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/media\/67125"}],"wp:attachment":[{"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/media?parent=67123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/categories?post=67123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/tags?post=67123"},{"taxonomy":"magazine-region","embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine-region?post=67123"},{"taxonomy":"magazine-series","embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine-series?post=67123"},{"taxonomy":"magazine-topic","embeddable":true,"href":"https:\/\/brainstation.io\/wp\/api\/wp\/v2\/magazine-topic?post=67123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}